In late 2021, Quanterix announced that its Simoa® phospho-Tau 181 (pTau181) blood test was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). A distinction not shared by any other company.
Related Posts
Building Custom High-Plex Biomarker Panels
Scale Your Spatial Discoveries with Molecular Barcoding
Spatial Analysis
PhenoCode Molecular Barcoding Kit
Introducing the Metabolism Spike-in Module for IO60
Neurology
NfL Fact Sheet
Neurofilament light (NfL) has emerged in recent years as a blood-based biomarker with the potential to aid in the improvement of early diagnosis and patient care of neuro-axonal injury and…
Neurology
Cytokine 4-Plex Advantage PLUS Product Flyer
Ultra-Sensitive, Fully Automated Simoa® Cytokine 4-Plex Advantage PLUS Assays Three panels, 11 essential cytokine biomarkers, femtogram sensitivity With Simoa® ultra-sensitive protein quantification, the cutting-edge Advantage PLUS assay platform, and full…
PhenoCode Discovery Immune Activation and Proliferation Human Protein Module
Neurology
Brain-Derived Tau (BD-Tau) Fact Sheet
Brain-derived Tau (BD-Tau) is one of the latest additions to the growing neurology biomarker family that holds promise to improve the accuracy in the identification and staging of neurodegeneration in…